StudyManager Unveils Reveal Version 3.3
StudyManager
announced the release of
Reveal 3.3
, with enhanced features that provide greater ease of use and performance for research sites, academic medical centers, and hospitals.
Based on customer feedback and StudyManager’s nearly 20 years in the field, Reveal 3.3 offers a number of key ease-of-use and productivity enhancements, including:
- Study budget interface, enabling faster review of budgeted payables.
- A “Next Appointment” feature, which provides at-a-glance patient information, helping coordinators prepare for upcoming appointments.
- A capability allowing users to project and review patient visit “windows," helping to improve protocol compliance.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
FDA Expands Farapulse PFA Approval to Persistent AF After Strong ADVANTAGE AF Trial Results
July 7th 2025Boston Scientific’s Farapulse Pulsed Field Ablation System is now approved for treating persistent atrial fibrillation, following 12-month data from the ADVANTAGE AF trial showing strong safety, high freedom from AF, and no major complications.
